COMBINATION OF DRONEDARONE WITH AT LEAST ONE DIURETIC, AND THERAPEUTIC USE THEREOF

1 . A method of preventing cardiovascular hospitalizations or mortality in a patient having a history of atrial fibrillation or atrial flutter, comprising administering an effective amount of dronedarone to said patient in combination with one or more diuretic.

2 . A method for regulating the potassium level in the blood of a patient, comprising administering an effective amount of dronedarone to said patient in combination with at least one diuretic.

3 . A method for treating atrial fibrillation or atrial flutter in patient with a history of atrial fibrillation or atrial flutter, comprising administering an effective amount of dronedarone to said patient in combination with one or more diuretic.

4 . The method according to anyone of claims 1 to 3 , wherein said diuretic is a non-potassium-sparing diuretic.

5 . The method according to claim 4 , wherein hypokalaemia is prevented.

6 . The method according to anyone of claims 1 to 3 , wherein the patient also exhibits at least one risk factors selected from the group consisting of:

hypertension,

diabetes,

history of cerebral stroke or of systemic embolism,

left atrial diameter greater than or equal to 50 mm measured by echocardiography, and

left ventricular ejection fraction less than 40%, measured by two-dimensional echography.

7 . The method according to any one of claims 1 to 3 , wherein the patient also exhibits at least one pathology selected from the group consisting of:

hypertension,

underlying structural heart disease,

tachycardia,

coronary disease,

non-rheumatic heart valve disease,

dilated cardiomyopathy of ischemic origin,

catheter ablation of atrial fibrillation or flutter,

supraventricular tachycardia other than atrial fibrillation or flutter,

history of valve surgery,

non-ischemic dilated cardiomyopathy,

hypertrophic cardiomyopathy,

rheumatic valve disease,

sustained ventricular tachycardia,

congenital cardiopathy,

catheter ablation for tachycardia other than for atrial fibrillation or flutter,

ventricular fibrillation,

and/or at least one cardiac device chosen from:

a cardiac stimulator, and

an implantable defibrillator (“ICD”).

8 . The method according to any one of claims 1 to 3 , wherein the dose of dronedarone administered per day, orally, is up to 800 mg, taken in one or more intakes.

9 . A combination of dronedarone, or a pharmaceutically acceptable salt thereof, and at least one diuretic, with the exclusion of furosemide, of hydrochlorothiazide, of metolazone, of amiloride, of spironolactone and of mannitol.

10 . The combination according to claim 9 , wherein said at least one diuretic is a non-potassium-sparing diuretic, with the exclusion of furosemide, of hydrochlorothiazide, of metolazone and of mannitol.